OncoMatch/Clinical Trials/NCT05489289
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Is NCT05489289 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies AK104 for hepatocellular carcinoma.
Treatment: AK104 — The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–0(Fully active)
Demographics
Prior therapy
Must have received: radical surgery — curative resection
Receiving radical resection as the only anti-tumor treatment
Cannot have received: any anti-tumor treatment other than radical surgery
Any anti-tumor treatment other than radical surgery before randomization
Lab requirements
Liver function
Child-Pugh grade: A; Precarious liver function indicated by severe complications [excluded]
Cardiac function
Poorly controlled or symptomatic hypertension, congestive heart failure, arrhythmia, etc [excluded]
Child-Pugh grade: A; Precarious liver function indicated by severe complications [excluded]; Poorly controlled or symptomatic hypertension, congestive heart failure, arrhythmia, etc [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05489289 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages